For sponsors preparing clinical trial data for regulatory review, the difference between SDTM and ADaM is more than a technical programming distinction. It affects how data are standardized, how analysis results are reproduced, how reviewers navigate the submission package, and how clearly the evidence can be traced from collected data to final outputs.
SDTM and ADaM are often discussed together because they sit close to each other in the clinical data flow. However, they answer different questions. SDTM asks: how should collected clinical trial data be organized and presented in a standard tabulation structure? ADaM asks: how should analysis datasets be structured so statistical analyses can be performed, reproduced, reviewed, and traced back to source data?
Understanding this relationship is important for sponsors because issues in either layer can create delays, review questions, or avoidable rework late in the submission process.

SDTM: standardized representation of collected study data

SDTM, the Study Data Tabulation Model, is designed to organize clinical trial data into standardized domains and variables. It provides a consistent structure for data collected during the study, such as demographics, exposure, adverse events, concomitant medications, laboratory tests, vital signs, disposition, and other subject-level or event-level information.

The purpose of SDTM is not to conduct the final statistical analysis. Its purpose is to represent collected study data in a standardized, reviewable format. This allows reviewers and downstream teams to understand what was collected, how it was organized, and how it aligns with CDISC expectations.

For sponsors, SDTM quality depends heavily on upstream decisions: CRF design, data collection conventions, controlled terminology, external data specifications, query resolution, coding, and reconciliation. A technically valid SDTM package can still create review friction if mapping decisions are unclear, supplemental qualifiers are overused, trial design domains are weak, or source data issues were not resolved earlier.

ADaM: analysis-ready data with traceability

ADaM, the Analysis Data Model, is built to support statistical analysis. ADaM datasets are designed around the analyses described in the statistical analysis plan, including endpoints, populations, derivations, censoring rules, baseline definitions, visit windows, imputation rules, and analysis flags.

ADaM is where clinical, statistical, and programming decisions become operational. For example, a simple efficacy endpoint may require derivations from multiple SDTM domains, protocol-defined visit windows, baseline logic, handling of missing values, population flags, and treatment-emergent definitions. ADaM brings these pieces together in a structure that allows the analysis to be performed and reviewed.

The key principle is traceability. A reviewer should be able to understand how an analysis result was produced, which ADaM variables contributed to it, and how those ADaM variables trace back to SDTM and, where needed, source data.

SDTM vs ADaM: Why They Are Not Interchangeable?

A common misconception is that SDTM and ADaM are two versions of the same data. They are not.
SDTM is organized around collected data. ADaM is organized around analysis. SDTM focuses on standard domains and tabulation. ADaM focuses on analysis concepts, derivations, populations, parameters, and results.
This distinction matters because trying to use SDTM as the direct analysis layer often creates unnecessary complexity. SDTM may not contain derived variables needed for analysis, may not express analysis populations in the required way, and may not be structured around the endpoints in the statistical analysis plan. Conversely, using ADaM to explain all collected data would blur the purpose of the analysis package and make review less efficient.
A strong submission package respects the purpose of each layer.

The SDTM to ADaM mapping relationship

In practice, ADaM development depends on well-structured SDTM data and well-defined analysis requirements. The mapping from SDTM to ADaM should not be treated as a purely mechanical conversion. It is a controlled, documented process that reflects the statistical analysis plan and the clinical meaning of the data.
Examples include:

• Creating ADSL as the subject-level analysis dataset using demographics, treatment assignment, disposition, exposure, randomization, and population definitions.
• Building BDS datasets for efficacy, laboratory, vital signs, or other repeated measurements, with analysis values, parameters, baseline values, changes from baseline, visit windows, and analysis flags.
• Creating occurrence-style datasets when the analysis requires event-level structures.
• Defining treatment-emergent logic for adverse events using exposure and event timing.
• Deriving responder variables, time-to-event variables, or composite endpoints according to the SAP.

The programming challenge is not only to derive the right variables. It is to make the derivations transparent, metadata-driven where appropriate, and reviewable.

Where sponsors run into trouble?

Problems often appear late in the process when SDTM and ADaM are developed in isolation or when the analysis strategy is not considered early enough.
Common issues include:

• SDTM domains that pass validation but do not support planned analysis efficiently.
• Inconsistent use of controlled terminology.
• Weak traceability between ADaM derivations and SDTM sources.
• Overly complex derivation logic that is not clearly documented.
• Analysis population flags that are not aligned with the protocol and SAP.
• Missing or inconsistent metadata.
• Late changes to endpoints or estimands that require ADaM rework.
• Reviewer guides that do not adequately explain key decisions.

These are not simply programming issues. They reflect cross-functional alignment between data management, biostatistics, statistical programming, medical writing, and regulatory strategy.

What good SDTM and ADaM delivery looks like?

A mature SDTM and ADaM workflow starts before programming begins. It includes review of the protocol, CRFs, data transfer specifications, external data sources, coding strategy, statistical analysis plan, and submission expectations.
Strong delivery usually includes:

• Early identification of critical domains and analysis datasets.
• Clear SDTM mapping specifications.
• Controlled terminology planning.
• Consistent handling of external data.
• ADaM specifications aligned with the SAP.
• Traceable derivations from ADaM back to SDTM.
• Independent quality control for datasets and outputs.
• Validation review beyond automated conformance checks.
• Define-XML, ADRG, and SDRG documentation that explains the package clearly.

How We Bridge SDTM and ADaM at Bioforum?

At Bioforum, SDTM and ADaM are treated as connected components of a submission-ready clinical data strategy. Our statistical programming teams work closely with data management and biostatistics to ensure that standardization, analysis, traceability, and reviewer documentation are aligned from the start.
This integrated approach is especially important for complex studies, legacy conversions, ISS and ISE integrations, rescue work, and programs moving toward regulatory submission. The goal is not only to produce datasets that validate. The goal is to produce datasets that support efficient analysis, regulatory review, and scientific confidence.

The Bottom Line for Sponsors

The difference between SDTM and ADaM is the difference between standardized collected data and analysis-ready data. SDTM provides the tabulation structure. ADaM provides the analysis structure. Together, they create the traceable path from clinical data collection to statistical results.
For sponsors, the most important question is not only whether SDTM and ADaM datasets can be produced. It is whether they are designed, documented, and quality-controlled in a way that supports analysis, review, and submission readiness.

Get Your Data Submission-Ready

Preparing SDTM, ADaM, or submission-ready analysis outputs? Bioforum’s statistical programming experts support CDISC-compliant datasets, TFLs, reviewer documentation, ISS and ISE integration, and independent quality review.